If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.

The center will conduct research and advance precision medicines for diabetes, pediatric rare diseases, cancer, and Alzheimer's disease.

Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.

The bill's passage through the committee improves the rare pediatric disease priority review voucher program's chances of being reauthorized before it expires Sept. 30.

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...